BIIB vs. SMMT: Biogen vs. Summit Therapeutics Stock Comparison
How do Biogen (BIIB) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Biogen (BIIB) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BIIB | SMMT |
|---|---|---|
| Name | Biogen Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 36.71 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | September 17, 1991 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIIB | SMMT |
|---|---|---|
| Total Return (1Y) | 65.44% | -2.48% |
| Total Return (3Y, Annualized) | 4.62% | 116.18% |
| Total Return (5Y, Annualized) | -0.96% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Biogen (BIIB) has a non-negative beta of 0.08.
| Metric | BIIB | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 34.58% | 75.06% |
| Beta (5Y) | 0.08 | -1.51 |
| Max Drawdown (5Y) | -64.35% | -87.64% |
| Avg. Volume (3M) | 1.05M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIIB | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 1.77 | -0.09 |
| Sortino Ratio (1Y) | 2.77 | -0.13 |
Profitability
ROE (TTM)
Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Biogen (BIIB) reports 1.87%, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.87%
- Max
- 109.18%
- Q3
- 6.23%
- BIIB
- 1.87%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
Both Biogen (BIIB) at 3.38% and Summit Therapeutics (SMMT) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.38%
- Max
- 18.05%
- Q3
- 4.78%
- BIIB
- 3.38%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Biogen (BIIB) at 24.12% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.12%
- Max
- 83.12%
- BIIB
- 24.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIIB | SMMT |
|---|---|---|
| ROE (TTM) | 1.87% | -220.01% |
| ROA (TTM) | 4.94% | -111.99% |
| Net Margin (TTM) | 3.38% | 0.00% |
| Operating Margin (TTM) | 24.12% | 0.00% |
| Gross Margin (TTM) | 75.77% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: Biogen (BIIB) reports revenue growth of 2.22%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.
EPS Growth
Only one side can be read here: Biogen (BIIB) reports EPS growth of -21.38%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.
Growth Metrics
| Metric | BIIB | SMMT |
|---|---|---|
| Revenue Growth (YoY) | 2.22% | -- |
| Revenue Growth (3Y CAGR) | -0.94% | -- |
| EPS Growth (YoY) | -21.38% | -- |
| EPS Growth (3Y CAGR) | -25.04% | -- |
Financial Strength
Current Ratio (MRQ)
Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Biogen (BIIB) at 1.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BIIB.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BIIB
- 1.95
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Biogen (BIIB) at 0.41 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41
- Max
- 1.42
- Q3
- 0.65
- BIIB
- 0.41
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIIB | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 1.95 | 5.99 |
| Debt / Equity (MRQ) | 0.41 | 0.04 |
| Net Debt / EBITDA | 1.97 | -- |
Dividends
Dividend Yield (TTM)
Neither Biogen (BIIB) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Biogen (BIIB) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIIB | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Biogen (BIIB) trades at 107.51 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.51
- BIIB
- 107.51
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for Biogen (BIIB), whose P/S ratio of 3.57 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.57
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIIB
- 3.57
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
Biogen (BIIB) at 1.94 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BIIB
- 1.94
- Q1
- 1.69
- Min
- -5.59
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIIB | SMMT |
|---|---|---|
| P/E Ratio (TTM) | 107.51 | -- |
| P/S Ratio (TTM) | 3.57 | -- |
| P/B Ratio (MRQ) | 1.94 | 23.13 |
| Free Cash Flow Yield (TTM) | 2.20% | -1.64% |